-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on April 12
Official announcement
On April 7, Medtronic announced the completion of the newly expanded Medtronic Engineering and Innovation Research Center (MEIC) in Hyderabad, India.
The R&D center is expected to spend US$160 million (approximately RMB 1 billion) to build Medtronic in the United States.
The largest R&D center outside.
The R&D center is expected to spend US$160 million (approximately RMB 1 billion) to build Medtronic in the United States.
The largest R&D center outside.
Medtronic CEO Geoff Martha (Geoff Martha) said: "In view of the market size and the availability of high-level talent pool, India is transforming into a global R&D center.
"
"
According to reports, the number of employees in the R&D center will increase from the current 350 to about 1,000.
The center will provide the company with software and engineering services in the fields of heart, nerve, kidney and minimally invasive surgery.
The center will provide the company with software and engineering services in the fields of heart, nerve, kidney and minimally invasive surgery.
Combining with the fact that the R&D centers of Pfizer, Eli Lilly, Novartis and other foreign companies have continuously withdrawn from China in recent years, Medtronic's establishment of the largest overseas R&D center in India cannot help but make people wonder.
After the R&D centers of foreign companies withdraw from China, where do they go?
After the R&D centers of foreign companies withdraw from China, where do they go?
Why was it built in India?
In August 2020, Medtronic announced that it would invest US$160 million to expand its R&D center in Hyderabad, India, to build the largest Engineering and Innovation Center (MEIC) outside of the United States.
On April 7, Medtronic announced that the expansion project was officially completed.
On April 7, Medtronic announced that the expansion project was officially completed.
In 1989, Medtronic by pharmnet.
com.
cn/agent_product/" target="_blank">proxy business quietly products into the Chinese market, Medtronic began the development of the China trip.
After 30 years of development, with first-class equipment and technology, Medtronic has occupied the high-end market of medical equipment in China .
The president of Medtronic Greater China once stated that China will definitely become Medtronic's largest market in the world.
com.
cn/agent_product/" target="_blank">proxy business quietly products into the Chinese market, Medtronic began the development of the China trip.
After 30 years of development, with first-class equipment and technology, Medtronic has occupied the high-end market of medical equipment in China .
The president of Medtronic Greater China once stated that China will definitely become Medtronic's largest market in the world.
When it comes to Medtronic’s market, Medtronic’s financial report data shows that in the third quarter of fiscal 2021, Medtronic’s revenue in the United States was US$3.
939 billion, accounting for 51% of the company’s revenue; the developed market revenue outside the US was US$2.
522 billion, accounting for the company’s revenue 32%; Emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue.
Among them, the overall organic growth of the Chinese market showed a mid-single-digit upward trend.
939 billion, accounting for 51% of the company’s revenue; the developed market revenue outside the US was US$2.
522 billion, accounting for the company’s revenue 32%; Emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue.
Among them, the overall organic growth of the Chinese market showed a mid-single-digit upward trend.
Globally, my country is currently the world's second largest pharmaceutical market, with a market size of more than 2.
3 trillion yuan.
According to data from the National Bureau of Statistics, the operating income of enterprises above designated size in China's pharmaceutical manufacturing industry reached 2390.
86 billion yuan in 2019, a year-on-year increase of 87.
4%.
3 trillion yuan.
According to data from the National Bureau of Statistics, the operating income of enterprises above designated size in China's pharmaceutical manufacturing industry reached 2390.
86 billion yuan in 2019, a year-on-year increase of 87.
4%.
However, with such a large market size and market potential, why did Medtronic build its largest overseas R&D center in India? Does Medtronic have to withdraw from the Chinese market like other foreign companies?
A large number of R&D centers are retreating
In the 1990s, China’s market economy began to take off, and the country’s opening to the outside world increased.
At the same time , the development technology of domestic medical equipment and drugs was relatively backward.
Foreign-funded pharmaceutical companies and machinery companies that started from medical technology exchanges began to flourish and settle in China.
market.
At the same time , the development technology of domestic medical equipment and drugs was relatively backward.
Foreign-funded pharmaceutical companies and machinery companies that started from medical technology exchanges began to flourish and settle in China.
market.
However, these R&D centers eventually failed and most of them could not escape the fate of retreat and closure.
In 1997, AstraZeneca established a research and development center in China.
In November 2017, AstraZeneca spun off preclinical research and established Dizhe Pharmaceutical in the form of a spin-off .
In November 2017, AstraZeneca spun off preclinical research and established Dizhe Pharmaceutical in the form of a spin-off .
Pfizer established Pfizer China R&D Center and Pfizer Wuhan R&D Center in China in 2005 and 2010 respectively, but by the end of 2019, it was closed due to plans to stop the launch of the Asian Discovery Lab.
Eli Lilly established two research centers in China in 2010 and 2012, but both closed in 2017.
The dividends of multinational corporations are no longer?
Multinational pharmaceutical companies have entered China for more than 30 years.
The development of major companies in China has actually demonstrated the development of China's pharmaceutical environment.
The development of major companies in China has actually demonstrated the development of China's pharmaceutical environment.
From the vigorous march into the Chinese market and the establishment of R&D centers, many companies have been retreating from China steadily.
The reason is that it is inseparable from China's growing medical technology and increasingly complete national policies.
The reason is that it is inseparable from China's growing medical technology and increasingly complete national policies.
At present, China's pharmaceuticals and medical equipment have entered a period of rapid development.
Domestic pharmaceutical companies represented by Hengrui and WuXi AppTec have entered a mature stage of development; and medical equipment companies such as Mindray and Lepu have also become domestic equipment.
Leading companies in China, domestically produced equipment has even realized domestically produced substitutes for imports in some areas.
The continuous development of domestic medical technology has made the price-performance ratio of domestic medical products in sharp contrast with that of multinational companies, and the era of multinational companies has gradually been replaced.
Domestic pharmaceutical companies represented by Hengrui and WuXi AppTec have entered a mature stage of development; and medical equipment companies such as Mindray and Lepu have also become domestic equipment.
Leading companies in China, domestically produced equipment has even realized domestically produced substitutes for imports in some areas.
The continuous development of domestic medical technology has made the price-performance ratio of domestic medical products in sharp contrast with that of multinational companies, and the era of multinational companies has gradually been replaced.
At the same time, China's centralized procurement policy for medicines, medical devices and other medical supplies has been gradually improved, the list of centralized procurement and drugs has been continuously expanded, and the supervision of imported drugs and medical devices has been strengthened.
Based on the consideration of many factors, some foreign companies have given up participating in centralized procurement.
However, under the current situation that volume procurement is normal, not entering centralized procurement means that sales have been lost.
Based on the consideration of many factors, some foreign companies have given up participating in centralized procurement.
However, under the current situation that volume procurement is normal, not entering centralized procurement means that sales have been lost.
An important reason why multinational companies set up R&D centers in China is because they can speed up the application of new drugs in China.
After China joined the International Technical Coordination Council for Human Drug Registration (ICH) in 2017, the results of R&D data between China and Europe and the United States Mutual certification has been achieved, and the R&D centers of many multinational companies have become unnecessary.
After China joined the International Technical Coordination Council for Human Drug Registration (ICH) in 2017, the results of R&D data between China and Europe and the United States Mutual certification has been achieved, and the R&D centers of many multinational companies have become unnecessary.
Different from the market ten years ago, nowadays, if foreign companies cannot produce amazing products, it is difficult for foreign companies to have the right to speak in China’s fast-growing pharmaceutical market.
With the development of China’s science and technology, the pharmaceutical industry and the medical device industry The pattern is changing.
With the development of China’s science and technology, the pharmaceutical industry and the medical device industry The pattern is changing.
Although many multinational pharmaceutical companies still occupy a share of the Chinese market, they have to admit that shrinking investment strategies in China has become a major trend.
Medical Network News on April 12
Official announcement
On April 7, Medtronic announced the completion of the newly expanded Medtronic Engineering and Innovation Research Center (MEIC) in Hyderabad, India.
The R&D center is expected to spend US$160 million (approximately RMB 1 billion) to build Medtronic in the United States.
The largest R&D center outside.
The R&D center is expected to spend US$160 million (approximately RMB 1 billion) to build Medtronic in the United States.
The largest R&D center outside.
Medtronic CEO Geoff Martha (Geoff Martha) said: "In view of the market size and the availability of high-level talent pool, India is transforming into a global R&D center.
"
"
According to reports, the number of employees in the R&D center will increase from the current 350 to about 1,000.
The center will provide the company with software and engineering services in the fields of heart, nerve, kidney and minimally invasive surgery.
The center will provide the company with software and engineering services in the fields of heart, nerve, kidney and minimally invasive surgery.
Combining with the fact that the R&D centers of Pfizer, Eli Lilly, Novartis and other foreign companies have continuously withdrawn from China in recent years, Medtronic's establishment of the largest overseas R&D center in India cannot help but make people wonder.
After the R&D centers of foreign companies withdraw from China, where do they go?
After the R&D centers of foreign companies withdraw from China, where do they go?
Why was it built in India?
In August 2020, Medtronic announced that it would invest US$160 million to expand its R&D center in Hyderabad, India, to build the largest Engineering and Innovation Center (MEIC) outside of the United States.
On April 7, Medtronic announced that the expansion project was officially completed.
On April 7, Medtronic announced that the expansion project was officially completed.
In 1989, Medtronic by pharmnet.
com.
cn/agent_product/" target="_blank">proxy business quietly products into the Chinese market, Medtronic began the development of the China trip.
After 30 years of development, with first-class equipment and technology, Medtronic has occupied the high-end market of medical equipment in China .
The president of Medtronic Greater China once stated that China will definitely become Medtronic's largest market in the world.
com.
cn/agent_product/" target="_blank">proxy business quietly products into the Chinese market, Medtronic began the development of the China trip.
After 30 years of development, with first-class equipment and technology, Medtronic has occupied the high-end market of medical equipment in China .
The president of Medtronic Greater China once stated that China will definitely become Medtronic's largest market in the world.
When it comes to Medtronic’s market, Medtronic’s financial report data shows that in the third quarter of fiscal 2021, Medtronic’s revenue in the United States was US$3.
939 billion, accounting for 51% of the company’s revenue; the developed market revenue outside the US was US$2.
522 billion, accounting for the company’s revenue 32%; Emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue.
Among them, the overall organic growth of the Chinese market showed a mid-single-digit upward trend.
939 billion, accounting for 51% of the company’s revenue; the developed market revenue outside the US was US$2.
522 billion, accounting for the company’s revenue 32%; Emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue.
Among them, the overall organic growth of the Chinese market showed a mid-single-digit upward trend.
Globally, my country is currently the world's second largest pharmaceutical market, with a market size of more than 2.
3 trillion yuan.
According to data from the National Bureau of Statistics, the operating income of enterprises above designated size in China's pharmaceutical manufacturing industry reached 2390.
86 billion yuan in 2019, a year-on-year increase of 87.
4%.
3 trillion yuan.
According to data from the National Bureau of Statistics, the operating income of enterprises above designated size in China's pharmaceutical manufacturing industry reached 2390.
86 billion yuan in 2019, a year-on-year increase of 87.
4%.
However, with such a large market size and market potential, why did Medtronic build its largest overseas R&D center in India? Does Medtronic have to withdraw from the Chinese market like other foreign companies?
A large number of R&D centers are retreating
In the 1990s, China’s market economy began to take off, and the country’s opening to the outside world increased.
At the same time , the development technology of domestic medical equipment and drugs was relatively backward.
Foreign-funded pharmaceutical companies and machinery companies that started from medical technology exchanges began to flourish and settle in China.
market.
At the same time , the development technology of domestic medical equipment and drugs was relatively backward.
Foreign-funded pharmaceutical companies and machinery companies that started from medical technology exchanges began to flourish and settle in China.
market.
However, these R&D centers eventually failed and most of them could not escape the fate of retreat and closure.
In 1997, AstraZeneca established a research and development center in China.
In November 2017, AstraZeneca spun off preclinical research and established Dizhe Pharmaceutical in the form of a spin-off .
In November 2017, AstraZeneca spun off preclinical research and established Dizhe Pharmaceutical in the form of a spin-off .
Pfizer established Pfizer China R&D Center and Pfizer Wuhan R&D Center in China in 2005 and 2010 respectively, but by the end of 2019, it was closed due to plans to stop the launch of the Asian Discovery Lab.
Eli Lilly established two research centers in China in 2010 and 2012, but both closed in 2017.
The dividends of multinational corporations are no longer?
Multinational pharmaceutical companies have entered China for more than 30 years.
The development of major companies in China has actually demonstrated the development of China's pharmaceutical environment.
The development of major companies in China has actually demonstrated the development of China's pharmaceutical environment.
From the vigorous march into the Chinese market and the establishment of R&D centers, many companies have been retreating from China steadily.
The reason is that it is inseparable from China's growing medical technology and increasingly complete national policies.
The reason is that it is inseparable from China's growing medical technology and increasingly complete national policies.
At present, China's pharmaceuticals and medical equipment have entered a period of rapid development.
Domestic pharmaceutical companies represented by Hengrui and WuXi AppTec have entered a mature stage of development; and medical equipment companies such as Mindray and Lepu have also become domestic equipment.
Leading companies in China, domestically produced equipment has even realized domestically produced substitutes for imports in some areas.
The continuous development of domestic medical technology has made the price-performance ratio of domestic medical products in sharp contrast with that of multinational companies, and the era of multinational companies has gradually been replaced.
Domestic pharmaceutical companies represented by Hengrui and WuXi AppTec have entered a mature stage of development; and medical equipment companies such as Mindray and Lepu have also become domestic equipment.
Leading companies in China, domestically produced equipment has even realized domestically produced substitutes for imports in some areas.
The continuous development of domestic medical technology has made the price-performance ratio of domestic medical products in sharp contrast with that of multinational companies, and the era of multinational companies has gradually been replaced.
At the same time, China's centralized procurement policy for medicines, medical devices and other medical supplies has been gradually improved, the list of centralized procurement and drugs has been continuously expanded, and the supervision of imported drugs and medical devices has been strengthened.
Based on the consideration of many factors, some foreign companies have given up participating in centralized procurement.
However, under the current situation that volume procurement is normal, not entering centralized procurement means that sales have been lost.
Based on the consideration of many factors, some foreign companies have given up participating in centralized procurement.
However, under the current situation that volume procurement is normal, not entering centralized procurement means that sales have been lost.
An important reason why multinational companies set up R&D centers in China is because they can speed up the application of new drugs in China.
After China joined the International Technical Coordination Council for Human Drug Registration (ICH) in 2017, the results of R&D data between China and Europe and the United States Mutual certification has been achieved, and the R&D centers of many multinational companies have become unnecessary.
After China joined the International Technical Coordination Council for Human Drug Registration (ICH) in 2017, the results of R&D data between China and Europe and the United States Mutual certification has been achieved, and the R&D centers of many multinational companies have become unnecessary.
Different from the market ten years ago, nowadays, if foreign companies cannot produce amazing products, it is difficult for foreign companies to have the right to speak in China’s fast-growing pharmaceutical market.
With the development of China’s science and technology, the pharmaceutical industry and the medical device industry The pattern is changing.
With the development of China’s science and technology, the pharmaceutical industry and the medical device industry The pattern is changing.
Although many multinational pharmaceutical companies still occupy a share of the Chinese market, they have to admit that shrinking investment strategies in China has become a major trend.
Medical Network News on April 12
Official announcement
Official announcement On April 7, Medtronic announced the completion of the newly expanded Medtronic Engineering and Innovation Research Center (MEIC) in Hyderabad, India.
The R&D center is expected to spend US$160 million (approximately RMB 1 billion) to build Medtronic in the United States.
The largest R&D center outside.
The R&D center is expected to spend US$160 million (approximately RMB 1 billion) to build Medtronic in the United States.
The largest R&D center outside.
Medtronic CEO Geoff Martha (Geoff Martha) said: "In view of the market size and the availability of high-level talent pool, India is transforming into a global R&D center.
"
"
According to reports, the number of employees in the R&D center will increase from the current 350 to about 1,000.
The center will provide the company with software and engineering services in the fields of heart, nerve, kidney and minimally invasive surgery.
The center will provide the company with software and engineering services in the fields of heart, nerve, kidney and minimally invasive surgery.
Combining with the fact that the R&D centers of Pfizer, Eli Lilly, Novartis and other foreign companies have continuously withdrawn from China in recent years, Medtronic's establishment of the largest overseas R&D center in India cannot help but make people wonder.
After the R&D centers of foreign companies withdraw from China, where do they go?
After the R&D centers of foreign companies withdraw from China, where do they go?
Why was it built in India?
Why was it built in India? In August 2020, Medtronic announced that it would invest US$160 million to expand its R&D center in Hyderabad, India, to build the largest Engineering and Innovation Center (MEIC) outside of the United States.
On April 7, Medtronic announced that the expansion project was officially completed.
On April 7, Medtronic announced that the expansion project was officially completed.
In 1989, Medtronic by pharmnet.
com.
cn/agent_product/" target="_blank">proxy business quietly products into the Chinese market, Medtronic began the development of the China trip.
After 30 years of development, with first-class equipment and technology, Medtronic has occupied the high-end market of medical equipment in China .
The president of Medtronic Greater China once stated that China will definitely become Medtronic's largest market in the world.
pharmnet. com.
cn/agent_product/" target="_blank">proxy business quietly products into the Chinese market, Medtronic began the development of the China trip.
After 30 years of development, with first-class equipment and technology, Medtronic has occupied the high-end market of medical equipment in China .
The president of Medtronic Greater China once stated that China will definitely become Medtronic's largest market in the world.
com.
cn/agent_product/" target="_blank">Actingpharmnet.
com.
cn/agent_product/" target="_blank"> Acting Acting medical equipment medical equipment medical equipment
When it comes to Medtronic’s market, Medtronic’s financial report data shows that in the third quarter of fiscal 2021, Medtronic’s revenue in the United States was US$3.
939 billion, accounting for 51% of the company’s revenue; the developed market revenue outside the US was US$2.
522 billion, accounting for the company’s revenue 32%; Emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue.
Among them, the overall organic growth of the Chinese market showed a mid-single-digit upward trend.
939 billion, accounting for 51% of the company’s revenue; the developed market revenue outside the US was US$2.
522 billion, accounting for the company’s revenue 32%; Emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue.
Among them, the overall organic growth of the Chinese market showed a mid-single-digit upward trend.
Globally, my country is currently the world's second largest pharmaceutical market, with a market size of more than 2.
3 trillion yuan.
According to data from the National Bureau of Statistics, the operating income of enterprises above designated size in China's pharmaceutical manufacturing industry reached 2390.
86 billion yuan in 2019, a year-on-year increase of 87.
4%.
Enterprise business enterprise3 trillion yuan.
According to data from the National Bureau of Statistics, the operating income of enterprises above designated size in China's pharmaceutical manufacturing industry reached 2390.
86 billion yuan in 2019, a year-on-year increase of 87.
4%.
However, with such a large market size and market potential, why did Medtronic build its largest overseas R&D center in India? Does Medtronic have to withdraw from the Chinese market like other foreign companies?
A large number of R&D centers are retreating
A large number of R&D centers are retreating In the 1990s, China’s market economy began to take off, and the country’s opening to the outside world increased.
At the same time , the development technology of domestic medical equipment and drugs was relatively backward.
Foreign-funded pharmaceutical companies and machinery companies that started from medical technology exchanges began to flourish and settle in China.
market.
Medicine, medicine, medicineAt the same time , the development technology of domestic medical equipment and drugs was relatively backward.
Foreign-funded pharmaceutical companies and machinery companies that started from medical technology exchanges began to flourish and settle in China.
market.
However, these R&D centers eventually failed and most of them could not escape the fate of retreat and closure.
In 1997, AstraZeneca established a research and development center in China.
In November 2017, AstraZeneca spun off preclinical research and established Dizhe Pharmaceutical in the form of a spin-off .
Medicine Medicine MedicineIn November 2017, AstraZeneca spun off preclinical research and established Dizhe Pharmaceutical in the form of a spin-off .
Pfizer established Pfizer China R&D Center and Pfizer Wuhan R&D Center in China in 2005 and 2010 respectively, but by the end of 2019, it was closed due to plans to stop the launch of the Asian Discovery Lab.
Eli Lilly established two research centers in China in 2010 and 2012, but both closed in 2017.
The dividends of multinational corporations are no longer?
The dividends of multinational corporations are no longer? Multinational pharmaceutical companies have entered China for more than 30 years.
The development of major companies in China has actually demonstrated the development of China's pharmaceutical environment.
The development of major companies in China has actually demonstrated the development of China's pharmaceutical environment.
From the vigorous march into the Chinese market and the establishment of R&D centers, many companies have been retreating from China steadily.
The reason is that it is inseparable from China's growing medical technology and increasingly complete national policies.
The reason is that it is inseparable from China's growing medical technology and increasingly complete national policies.
At present, China's pharmaceuticals and medical equipment have entered a period of rapid development.
Domestic pharmaceutical companies represented by Hengrui and WuXi AppTec have entered a mature stage of development; and medical equipment companies such as Mindray and Lepu have also become domestic equipment.
Leading companies in China, domestically produced equipment has even realized domestically produced substitutes for imports in some areas.
The continuous development of domestic medical technology has made the price-performance ratio of domestic medical products in sharp contrast with that of multinational companies, and the era of multinational companies has gradually been replaced.
Domestic pharmaceutical companies represented by Hengrui and WuXi AppTec have entered a mature stage of development; and medical equipment companies such as Mindray and Lepu have also become domestic equipment.
Leading companies in China, domestically produced equipment has even realized domestically produced substitutes for imports in some areas.
The continuous development of domestic medical technology has made the price-performance ratio of domestic medical products in sharp contrast with that of multinational companies, and the era of multinational companies has gradually been replaced.
At the same time, China's centralized procurement policy for medicines, medical devices and other medical supplies has been gradually improved, the list of centralized procurement and drugs has been continuously expanded, and the supervision of imported drugs and medical devices has been strengthened.
Based on the consideration of many factors, some foreign companies have given up participating in centralized procurement.
However, under the current situation that volume procurement is normal, not entering centralized procurement means that sales have been lost.
Based on the consideration of many factors, some foreign companies have given up participating in centralized procurement.
However, under the current situation that volume procurement is normal, not entering centralized procurement means that sales have been lost.
An important reason why multinational companies set up R&D centers in China is because they can speed up the application of new drugs in China.
After China joined the International Technical Coordination Council for Human Drug Registration (ICH) in 2017, the results of R&D data between China and Europe and the United States Mutual certification has been achieved, and the R&D centers of many multinational companies have become unnecessary.
After China joined the International Technical Coordination Council for Human Drug Registration (ICH) in 2017, the results of R&D data between China and Europe and the United States Mutual certification has been achieved, and the R&D centers of many multinational companies have become unnecessary.
Different from the market ten years ago, nowadays, if foreign companies cannot produce amazing products, it is difficult for foreign companies to have the right to speak in China’s fast-growing pharmaceutical market.
With the development of China’s science and technology, the pharmaceutical industry and the medical device industry The pattern is changing.
With the development of China’s science and technology, the pharmaceutical industry and the medical device industry The pattern is changing.
Although many multinational pharmaceutical companies still occupy a share of the Chinese market, they have to admit that shrinking investment strategies in China has become a major trend.
